The FDA has authorized a new treatment that may help immunocompromised people be protected from COVID-19. The treatment is a monoclonal antibody infusion that is expected to be available this April.
From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13 ...
More health systems across the U.S. are offering monoclonal antibody treatment as a way of fighting COVID-19 infection, but how exactly do the treatments work, and how effective are they in reducing ...
Monoclonal antibodies target specific disease molecules. They can help treat cancer, autoimmune disorders, and infectious diseases. Discover what you should know about this therapy. Monoclonal ...
For patients who rely on monoclonal antibodies and other biologic drugs, treatment often means hours tethered to an IV pole while a clear bag slowly empties into a vein. A new generation of ...
More than 3.5 million infusions of antibodies have been used to treat COVID. The treatment is being phased out because the antibodies have lost their efficacy against new variants of coronavirus. As ...
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the ...
PORTLAND, Oregon -- New research from Oregon Health & Science University and collaborators indicates lab-made antibodies may be able to cure people infected with yellow fever, a virus for which there ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results